1. Olaparib@human serum albumin nanoparticles as sustained drug-releasing tumour-targeting nanomedicine to inhibit growth and metastasis in the mouse model of triple-negative breast cancer
   Nageswara Rao Vysyaraju et al, 2022, Journal of Drug Targeting CrossRef
2. Inhibitors of PARP-1 exert inhibitory effects on the biological characteristics of hepatocellular carcinoma cells in vitro
   Xiaorong Mao et al, 2017, Molecular Medicine Reports CrossRef
3. Generation and characterization of a cell line from an intraductal tubulopapillary neoplasm of the pancreas
   Matthäus Felsenstein et al, 2020, Laboratory Investigation CrossRef
4. PARP Inhibitors in Pancreatic Cancer
   Timothy J. Brown et al, 2021, The Cancer Journal CrossRef
5. Ultrasensitive electrochemical detection of poly (ADP-ribose) polymerase-1 via polyaniline deposition
   Yong Liu et al, 2018, Talanta CrossRef
6. PARP1 inhibition by Olaparib reduces the lethality of pancreatic cancer cells and increases their sensitivity to Gemcitabine
   Francisco Quiñonero et al, 2022, Biomedicine & Pharmacotherapy CrossRef
7. Pre-activation of autophagy impacts response to olaparib in prostate cancer cells
   Maxime Cahuzac et al, 2022, Communications Biology CrossRef